AssetMark Inc
AVTX icon

AssetMark Inc’s Avalo Therapeutics AVTX Stock Holding History

AssetMark Inc’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407 Buy
+22
New +$348 ﹤0.01% 3320

Other funds holding AVTX

NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

AssetMark Inc's AVTX Position: Q2 2026 in Review

AssetMark Inc opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 22 shares worth $407. The stake represents ﹤0.01% of the portfolio and ranks #3320 among its holdings.

22 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • AssetMark Inc held 22 shares of Avalo Therapeutics worth $407 as of Q2 2026.
  • Avalo Therapeutics was a new AssetMark Inc position in Q2 2026.
  • Avalo Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3320 holding.
  • 22 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.